Burrill & Co. Launches Fourth Fund With $313 Million And Aims For More
This article was originally published in The Pink Sheet Daily
Executive Summary
Fresh from an exceptional return on its investment in recently-acquired Pharmasset, the San Francisco firm already has enough to make Burrill Capital Fund IV its largest fund yet.
You may also be interested in...
Rusnano’s Grand Ambitions In Biotech
Now on the ground in Silicon Valley, Russian sovereign fund Rusnano is investing broadly in nanotechnology around the globe, and a lot of those rubles are flowing to US biotech firms, with one major stipulation: help bring innovation and jobs back to Mother Russia.
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.
To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano
The U.S. biotechs, which are independent but share founders and investors, raise a combined $94.5 million from the Russian sovereign fund and U.S. venture firms.